Becton, Dickinson and Company (NYSE:BDX) Shares Bought by State Street Corp

State Street Corp boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,953,116 shares of the medical instruments supplier’s stock after buying an additional 106,616 shares during the quarter. State Street Corp owned 4.83% of Becton, Dickinson and Company worth $3,364,096,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in BDX. Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. M&G Plc raised its holdings in shares of Becton, Dickinson and Company by 0.9% in the 2nd quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock valued at $165,967,000 after purchasing an additional 6,052 shares in the last quarter. Benson Investment Management Company Inc. raised its holdings in shares of Becton, Dickinson and Company by 13.2% in the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after purchasing an additional 2,602 shares in the last quarter. Swedbank AB raised its holdings in shares of Becton, Dickinson and Company by 1.8% in the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock valued at $36,367,000 after purchasing an additional 2,729 shares in the last quarter. Finally, Curi RMB Capital LLC raised its holdings in shares of Becton, Dickinson and Company by 18.1% in the 3rd quarter. Curi RMB Capital LLC now owns 84,873 shares of the medical instruments supplier’s stock valued at $20,463,000 after purchasing an additional 13,030 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 0.4 %

NYSE BDX opened at $222.24 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm’s fifty day moving average price is $233.03 and its 200 day moving average price is $233.73. The company has a market capitalization of $64.25 billion, a price-to-earnings ratio of 37.41, a price-to-earnings-growth ratio of 1.65 and a beta of 0.41. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $3.42 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.87%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BDX. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.